IOL Chemicals and Pharmaceuticals Receives ₹2,05,94,796 Penalty Order from Customs Authority over FTA Exemption Dispute

1 min read     Updated on 09 May 2026, 04:29 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

IOL Chemicals and Pharmaceuticals Limited received an Order-In-Original on 08 May 2026 from the Additional Commissioner of Customs, Kandla, imposing a total levy of Rs. 2,05,94,796/-, comprising differential customs duty of Rs. 27,97,398/-, a penalty of Rs. 27,97,398/- under Section 114A, an additional penalty of Rs. 1,00,00,000/- under Section 114AA of the Customs Act, 1962, and a redemption fine of Rs. 50,00,000/-. The order alleges incorrect availment of ASEAN-India FTA exemption through Certificates of Origin not conforming to the prescribed format. The company intends to appeal the order and has stated the levy carries no material financial or operational impact.

powered bylight_fuzz_icon
39869943

*this image is generated using AI for illustrative purposes only.

IOL Chemicals & Pharmaceuticals Limited disclosed on 09 May 2026 that it has received an Order-In-Original (O-I-O) from the Additional Commissioner of Customs, Kandla, imposing a cumulative levy of Rs. 2,05,94,796/-. The order was received by the company on 08 May 2026 and was disclosed to the stock exchanges under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nature of the Order and Allegations

The Order-In-Original alleges that IOL Chemicals and Pharmaceuticals incorrectly availed exemption benefits under the ASEAN-India Free Trade Agreement (FTA) by submitting Certificates of Origin that did not conform to the prescribed format under Notification No. 46/2011-Customs read with ASEAN-India FTA Rules of Origin. The authority has confirmed a demand of differential Customs duty along with associated penalties and fines as a result of this alleged non-compliance.

Breakdown of the Levy

The total aggregate levy of Rs. 2,05,94,796/- comprises multiple components as detailed below:

Component: Details
Differential Customs Duty: Rs. 27,97,398/- (along with applicable interest)
Penalty under Section 114A, Customs Act, 1962: Rs. 27,97,398/-
Additional Penalty under Section 114AA, Customs Act, 1962: Rs. 1,00,00,000/-
Redemption Fine: Rs. 50,00,000/-
Total Aggregate Levy: Rs. 2,05,94,796/-

Company's Response and Financial Impact

IOL Chemicals and Pharmaceuticals has stated that it will be filing an appeal against this order with the appropriate authority. The company has also clarified that the aforesaid levy does not have any material impact on its financials, nor does it have any impact on its operational or other activities.

Disclosure Details

The requisite disclosure was made in accordance with Regulation 30 of the Listing Regulations, read with Clause 20 of Para A of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The disclosure was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary of IOL Chemicals and Pharmaceuticals Limited.

Historical Stock Returns for IOL Chemicals & Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.94%+2.72%+23.27%+6.87%+52.13%-24.84%

How might the outcome of IOL Chemicals' appeal against the customs order influence other Indian pharmaceutical companies currently availing ASEAN-India FTA exemption benefits?

Could this customs dispute signal a broader regulatory crackdown on Certificate of Origin compliance under India's FTA agreements, and which industries are most exposed?

If the appeal is unsuccessful, what precedent could this set for IOL Chemicals' future import strategies and sourcing decisions under preferential trade agreements?

IOL Chemicals & Pharmaceuticals
View Company Insights
View All News
like20
dislike

IOL Chemicals and Pharmaceuticals Promoters Declare No Encumbrance on Shares for FY26

1 min read     Updated on 05 May 2026, 03:49 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

IOL Chemicals and Pharmaceuticals Limited's promoter, Varinder Gupta, submitted a declaration dated 6th April 2026 confirming no encumbrance on promoter or promoter group shares during the financial year ended 31st March 2026. The declaration was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and covers nine entities including individuals and corporate bodies. It was addressed to NSE, BSE, and the company's Audit Committee.

powered bylight_fuzz_icon
39478769

*this image is generated using AI for illustrative purposes only.

IOL Chemicals & Pharmaceuticals has received a formal declaration from its promoter confirming that no encumbrance was created on the company's shares held by the promoter or promoter group, directly or indirectly, during the financial year ended 31st March 2026. The declaration was submitted by Varinder Gupta, Promoter of IOL Chemicals and Pharmaceuticals Ltd, from Ludhiana, and was addressed to the National Stock Exchange of India Ltd, BSE Limited, and the company's Audit Committee.

Declaration Under SEBI Regulation 31(4)

The declaration was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters and members of the promoter group to submit an annual declaration confirming the encumbrance status of their shareholding in the listed company. The submission was dated 6th April 2026 and pertains to the financial year ended 31st March 2026.

Promoter and Promoter Group Entities Covered

The declaration covers the following entities on whose behalf it has been submitted:

Name of Entity/Person Category
Varinder Gupta Promoter
Varinder Gupta (HUF) Promoter Group
Dimple Gupta Promoter Group
Vikas Gupta Promoter Group
Abhiraj Gupta Promoter Group
Vikas Gupta (HUF) Promoter Group
Mayadevi Polycot Limited Promoter Group
NM Merchantiles Limited Promoter Group
NCVI Enterprises Limited Promoter Group

Key Details of the Submission

The following table summarises the key parameters of the regulatory submission:

Parameter: Details
Declaration Date: 6th April 2026
Financial Year Covered: Ended 31st March 2026
Regulatory Provision: Regulation 31(4), SEBI (SAST) Regulations, 2011
Encumbrance Status: Nil
Submitted By: Varinder Gupta, Promoter
Place of Submission: Ludhiana

The declaration confirms that none of the shares held by the listed promoter and promoter group entities in IOL Chemicals and Pharmaceuticals Ltd were subject to any encumbrance, whether direct or indirect, during the relevant financial year. The submission was made to both major stock exchanges—NSE and BSE—as well as to the company's Audit Committee, in compliance with applicable SEBI regulations.

Historical Stock Returns for IOL Chemicals & Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.94%+2.72%+23.27%+6.87%+52.13%-24.84%

How might the consistent nil-encumbrance status of promoter shareholding influence institutional investor confidence and potential stake acquisition in IOL Chemicals & Pharmaceuticals going forward?

Could the clean promoter shareholding structure position IOL Chemicals & Pharmaceuticals more favorably for future fundraising activities such as QIPs or preferential allotments?

What strategic expansion or capital allocation plans might IOL Chemicals & Pharmaceuticals pursue in FY2027 given the financial stability implied by unencumbered promoter holdings?

IOL Chemicals & Pharmaceuticals
View Company Insights
View All News
like18
dislike

More News on IOL Chemicals & Pharmaceuticals

1 Year Returns:+52.13%